OrthoPediatrics' Q3 Losses Widen Amid Restructuring, Revenue Growth

TL;DR

**KIDS is burning cash and racking up debt despite revenue growth, making it a risky bet until profitability is clearly in sight.**

AI Summary

OrthoPediatrics Corp. (KIDS) reported a net loss of $11.773 million for the three months ended September 30, 2025, a significant increase from the $7.919 million net loss in the prior-year quarter. For the nine months ended September 30, 2025, the net loss widened to $29.545 million, compared to $21.753 million in the same period of 2024. Despite the increased losses, net revenue grew to $61.250 million for the quarter, up from $54.573 million, and to $174.743 million for the nine months, an increase from $152.060 million. Operating expenses surged to $54.702 million for the quarter, including a $2.268 million intangible asset impairment and $2.294 million in restructuring costs, contributing to an operating loss of $9.428 million. The company's cash balance decreased significantly from $43.820 million at December 31, 2024, to $16.826 million at September 30, 2025, while long-term debt increased from $23.957 million to $48.065 million. The accumulated deficit reached $265.109 million as of September 30, 2025, up from $235.564 million at December 31, 2024, indicating ongoing profitability challenges.

Why It Matters

OrthoPediatrics' continued net losses and increasing debt raise concerns for investors, despite consistent revenue growth. The significant cash burn, with cash dropping from $43.820 million to $16.826 million, suggests a need for careful liquidity management and potentially further financing, impacting shareholder value. For employees, restructuring costs of $5.305 million over nine months could signal job insecurity or operational shifts. Customers might see continued innovation in pediatric orthopedic devices, but the company's financial health could influence long-term product support and availability in a niche market where competition, though less direct, still exists from larger medical device companies with broader portfolios.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $265.109 million as of September 30, 2025, and a net loss of $29.545 million for the nine months ended September 30, 2025. Cash decreased from $43.820 million to $16.826 million, and long-term debt increased from $23.957 million to $48.065 million, indicating significant cash burn and increased leverage.

Analyst Insight

Investors should exercise caution and closely monitor OrthoPediatrics' path to profitability and cash flow management. Await clear signs of reduced operating losses and positive free cash flow before considering a significant investment, as current trends suggest ongoing financial strain despite revenue growth.

Financial Highlights

debt To Equity

0.41

revenue

$174.743M

operating Margin

-17.8%

total Assets

$493.486M

total Debt

$110.945M

net Income

-$29.545M

eps

N/A

gross Margin

73.0%

cash Position

$16.826M

revenue Growth

+14.9%

Key Numbers

• $11.773M — Net Loss (Q3 2025) (Increased from $7.919M in Q3 2024, indicating widening losses.)
• $29.545M — Net Loss (9M 2025) (Widened from $21.753M in 9M 2024, showing persistent unprofitability.)
• $61.250M — Net Revenue (Q3 2025) (Increased from $54.573M in Q3 2024, demonstrating top-line growth.)
• $174.743M — Net Revenue (9M 2025) (Increased from $152.060M in 9M 2024, showing consistent revenue expansion.)
• $265.109M — Accumulated Deficit (Increased from $235.564M at Dec 31, 2024, highlighting ongoing losses.)
• $16.826M — Cash (Sep 30, 2025) (Decreased significantly from $43.820M at Dec 31, 2024, indicating substantial cash burn.)
• $48.065M — Long-term Term Loan (Increased from $23.957M at Dec 31, 2024, reflecting increased debt financing.)
• $2.268M — Intangible Asset Impairment (Q3 2025) (New expense contributing to increased operating losses.)
• $2.294M — Restructuring Costs (Q3 2025) (New expense contributing to increased operating losses.)
• $15.199M — Net Cash Used in Operating Activities (9M 2025) (Reduced from $23.061M in 9M 2024, but still a significant outflow.)

Key Players & Entities

• ORTHOPEDIATRICS CORP (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• $11.773 million (dollar_amount) — net loss for three months ended September 30, 2025
• $29.545 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $61.250 million (dollar_amount) — net revenue for three months ended September 30, 2025
• $174.743 million (dollar_amount) — net revenue for nine months ended September 30, 2025
• $265.109 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $16.826 million (dollar_amount) — cash balance as of September 30, 2025
• $48.065 million (dollar_amount) — long-term term loan as of September 30, 2025

FAQ

Risk Factors

• Increasing Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $11.773 million for Q3 2025, an increase from $7.919 million in Q3 2024. For the nine months ended September 30, 2025, the net loss widened to $29.545 million from $21.753 million in the prior year. The accumulated deficit grew to $265.109 million as of September 30, 2025, up from $235.564 million at December 31, 2024, indicating persistent unprofitability.
• Deteriorating Cash Position and Increased Debt [high — financial]: Cash and cash equivalents decreased significantly from $43.820 million at December 31, 2024, to $16.826 million at September 30, 2025. Concurrently, long-term debt, primarily the term loan, increased from $23.957 million to $48.065 million, raising concerns about financial flexibility and leverage.
• Surge in Operating Expenses [medium — operational]: Operating expenses for Q3 2025 were $54.702 million, a substantial increase driven by a $2.268 million intangible asset impairment and $2.294 million in restructuring costs. This surge contributed to a wider operating loss of $9.428 million for the quarter.
• Inventory Growth [medium — operational]: Inventories, net, increased to $128.807 million as of September 30, 2025, from $117.005 million at December 31, 2024. While this could support revenue growth, it also ties up working capital and carries risks of obsolescence or write-downs.
• Increased Interest Expense [medium — financial]: Interest expense, net, more than tripled to $4.064 million for the nine months ended September 30, 2025, compared to $1.302 million in the same period of 2024. This is a direct consequence of the increased debt levels.
• Research and Development Decline [low — operational]: Research and development expenses decreased to $6.843 million for the nine months ended September 30, 2025, from $8.118 million in the prior year. While cost-saving, a sustained reduction could impact future product innovation and competitiveness.

Industry Context

OrthoPediatrics Corp. operates in the pediatric orthopedic device market, a specialized segment of the broader orthopedic industry. This niche focuses on developing and marketing implants and instruments for the treatment of congenital, developmental, and trauma-related orthopedic conditions in children. The market is characterized by a need for specialized product designs and regulatory compliance tailored to pediatric patients.

Regulatory Implications

As a medical device company, OrthoPediatrics is subject to stringent regulatory oversight by bodies like the FDA in the U.S. and similar agencies globally. Compliance with quality system regulations, pre-market approval processes, and post-market surveillance is critical. Any failures in compliance or product recalls could lead to significant financial penalties, reputational damage, and disruptions to sales.

What Investors Should Do

1. Monitor cash burn and debt levels closely.
2. Evaluate the sustainability of revenue growth against rising costs.
3. Assess the impact of restructuring and impairment charges.
4. Analyze the company's strategy for addressing its accumulated deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported increased net loss, revenue growth, significant cash burn, and increased debt.
• 2024-12-31: End of Fiscal Year 2024 — Provided the comparative balance sheet figures for assets, liabilities, and equity.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. (Indicates the company has historically incurred more losses than profits, impacting its ability to fund operations and growth internally.)

Intangible asset impairment

A charge taken when the carrying value of an intangible asset (like goodwill or patents) on the balance sheet is deemed to be higher than its recoverable amount. (Represents a non-cash expense that reduces net income and can signal issues with the underlying value of acquired assets or business segments.)

Restructuring costs

Expenses incurred when a company undergoes significant organizational changes, such as layoffs, facility closures, or business divestitures. (These are often one-time costs aimed at improving future efficiency, but they negatively impact current period profitability.)

Long-term term loan

A significant debt obligation that is due in more than one year, typically used for substantial capital expenditures or acquisitions. (An increase in this liability indicates the company is taking on more debt, which increases financial risk and interest expense.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (Represents the premium paid for factors like brand reputation, customer loyalty, or synergies, and is subject to impairment testing.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, OrthoPediatrics Corp. has demonstrated top-line revenue growth, with net revenue increasing by 12.2% for Q3 2025 ($61.250M vs $54.573M) and 14.9% for the nine months ($174.743M vs $152.060M). However, this growth has been overshadowed by significantly widening net losses, which increased from $7.919M to $11.773M in Q3 and from $21.753M to $29.545M for the nine months. Operating expenses have surged, partly due to new charges like intangible asset impairment and restructuring costs, leading to a higher operating loss. The company's financial position has weakened, with a substantial decrease in cash reserves and a significant increase in long-term debt.

Key Financial Figures

• $0.00025 — ange on which registered Common Stock, $0.00025 par value per share KIDS Nasdaq Global

Filing Documents

• kids-20250930.htm (10-Q) — 1010KB
• exhibit311-ceocertificatio.htm (EX-31.1) — 9KB
• exhibit312-cfocertificatio.htm (EX-31.2) — 9KB
• exhibit321-ceocertificatio.htm (EX-32.1) — 4KB
• exhibit322-cfocertificatio.htm (EX-32.2) — 5KB
• 0001425450-25-000114.txt ( ) — 6236KB
• kids-20250930.xsd (EX-101.SCH) — 47KB
• kids-20250930_cal.xml (EX-101.CAL) — 71KB
• kids-20250930_def.xml (EX-101.DEF) — 289KB
• kids-20250930_lab.xml (EX-101.LAB) — 606KB
• kids-20250930_pre.xml (EX-101.PRE) — 431KB
• kids-20250930_htm.xml (XML) — 663KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1 Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets - September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Operations - Three and Nine Months Ended S eptember 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive Loss - Three and Nine Months Ended Se ptember 30, 2025 and 2024 6 Condensed Consolidated Statements of Stockholders' Equity - Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2025 and 2024 9 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3 Quantitative and Qualitative Disclosures About Market Risk 36

Controls and Procedures

Item 4 Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1 Legal Proceedings 37

Risk Factors

Item 1A Risk Factors 37

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 38

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 38

Other Information

Item 5 Other Information 38

Exhibits

Item 6 Exhibits 39 Exhibit Index 40

Signatures

Signatures 42 NOTE REGARDING FORWARD-LOOKING STATEMENTS All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our a

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS ORTHOPEDIATRICS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In Thousands, Except Share Data) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash $ 16,826 $ 43,820 Restricted cash 2,058 1,957 Short-term investments 40,902 25,013 Accounts receivable - trade, net of allowances of $ 1,486 and $ 1,145 , respectively 51,274 42,357 Inventories, net 128,807 117,005 Prepaid expenses and other current assets 5,985 7,021 Total current assets 245,852 237,173 Property and equipment, net 51,204 50,596 Other assets: Amortizable intangible assets, net 63,262 64,427 Goodwill 103,613 93,844 Other intangible assets 15,941 16,752 Other non-current assets 13,614 10,417 Total other assets 196,430 185,440 Total assets $ 493,486 $ 473,209 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable - trade $ 7,164 $ 8,908 Accrued compensation and benefits 13,821 13,888 Current portion of long-term debt with affiliate 166 160 Current portion of acquisition installment payable 1,181 1,347 Other current liabilities 10,900 9,659 Total current liabilities 33,232 33,962 Long-term liabilities: Long-term term loan 48,065 23,957 Long-term convertible note 48,327 47,913 Long-term debt with affiliate, net of current portion 326 451 Other long-term debt, net of current portion 2,456 635 Acquisition installment payable, net of current portion 227 2,452 Deferred income taxes 3,804 3,381 Other long-term liabilities 7,740 5,892 Total long-term liabilities 110,945 84,681 Total liabilities 144,177 118,643 Stockholders' equity: Common stock, $ 0.00025 par value; 50,000,000 shares authorized; 25,077,330 shares and 24,217,508 shares issued as of September 30, 2025 and December 31, 2024, respectively 6 6 Additional paid-in capital 618,041 600,897 Accumulated deficit ( 265,109 ) ( 235,564 ) Accumulated other comprehensive loss ( 3,629 ) ( 10,773 ) Total stockholders' equity 349,309 354,566

View Full Filing

View this 10-Q filing on SEC EDGAR